Epicardial Ablation in Brugada Syndrome (BRUGADA_I)
Brugada Syndrome
About this trial
This is an interventional treatment trial for Brugada Syndrome focused on measuring radiofrequency ablation, mapping, sudden death, syncope
Eligibility Criteria
Inclusion Criteria:
- Patients affected by Brugada Syndrome, profiled by genetic testing, with documented spontaneous or drug-induced type I BrS ECG pattern, with symptoms attributable to ventricular arrhythmias and presenting multiple documented arrhythmic episodes
- Patients with an ICD already implanted
- Patients referred to the center for an electrophysiological study and indication to a potential concomitant radio-frequency catheter ablation (RFA) of ventricular arrhythmia or ventricular fibrillation
- Age ≥ 18
- Willingness to attend follow-up examinations
- Written informed consent to the participation in the trial
Exclusion Criteria:
- Pregnancy or breast-feeding
- Patients with low arrhythmic risk (Brugada pattern III)
- Life expectancy < 12 months.
Sites / Locations
- IRCCS Policlinico S. Donato
Arms of the Study
Arm 1
Experimental
mapping/ablation
Epicardial substrate identification consisted in mapping the entire RV epicardial surface under baseline conditions and after ajmaline infusion (1mg/kg in 5 minutes).We obtained 3 groups of RV epicardial maps using CARTO3 system: 1) bipolar/unipolar voltage map, 2) local activation time map (LAT), and 3) potential duration map (PDM), in which abnormal long-duration bipolar electrograms were defined as low-frequency (up to 100 Hz) prolonged duration (> 200 ms) bipolar signals with delayed activity extending beyond the end of the QRS complex. Epicardial ablation was performed during sinus rhythm using a stepwise strategy in a descending order of abnormal potential duration as displayed on the map and beginning from the longest potentials.